This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D82.0 | Synonyms: Immunodeficiency with thrombocytopenia and eczema, WAS-related immunodeficiency
Immunodeficiency with thrombocytopenia and eczema was first described in 1937 by the German pediatrician Alfred Wiskott, who reported it as an X-linked disease in which bleeding due to thrombocytopenia, eczema and recurrent infections occurred in three brothers. Later, in 1954, Robert A. Aldrich additionally reported the X-linked inheritance pattern in the United States, and it was named Wiskott-Aldrich syndrome (WAS).
In 1994, Derry et al. identified the WAS gene (Xp11.22-p11.23) encoding the WAS protein (WASP). WASP plays a key role in regulating rearrangement of the actin cytoskeleton and is expressed in all hematopoietic cells.
ICD-10 D82.0 is a code encompassing immunodeficiency with thrombocytopenia and eczema and conceptually overlaps with Wiskott-Aldrich syndrome. This code is also used for classifying the clinical phenotypes of WAS.
In Korea, WAS and related immunodeficiencies are listed as rare diseases, and diagnosis and treatment are provided at major pediatric hematology-immunology centers such as Samsung Medical Center and Seoul National University Children's Hospital.
The most common cause of immunodeficiency with thrombocytopenia and eczema is mutation of the WAS gene located on the short arm of the X chromosome (Xp11.22-23). More than 400 mutations have been reported to date, and missense, nonsense, frameshift and splice-site mutations all occur.
WAS gene mutations have a broad phenotypic spectrum. When protein expression is completely lost, classic WAS (triad of thrombocytopenia + eczema + immunodeficiency) results; when WASP function is partially preserved due to missense mutations, it presents as X-linked thrombocytopenia (XLT). Activating (gain-of-function) mutations of the WAS gene cause X-linked neutropenia (XLN).
Rarely, autoantibodies against WASP may be produced, resulting in an acquired WAS-like phenotype.
WAS is inherited in an X-linked recessive manner, and almost all patients are male. Female carriers may have mild symptoms depending on the X-chromosome inactivation (lyonization) pattern, but most are asymptomatic. About 1/3 arise from de novo mutations without a family history.
The WAS gene consists of 12 exons and encodes the WASP protein of 502 amino acids. WASP consists of the WH1 (WASP Homology 1), CRIB (CDC42/Rac interactive binding), PRD (proline-rich domain) and VCA (verprolin-cofilin-acidic) domains. The VCA domain carries the key function of binding the Arp2/3 complex and promoting F-actin polymerization.
Among missense mutations in exons 1–3, those that preserve the WH1 domain present mildly as XLT, while mutations causing loss of the protein present as classic WAS or severe WAS.
Worldwide, an incidence of about 1–10 per million live-born males is reported. WAS accounts for about 1–2% of all primary immunodeficiencies. Clustering of mutations due to a founder effect has been reported in specific ethnic groups or regions.
In Korea, WAS (including D82.0) is classified as a rare intractable disease and is eligible for rare disease Special Copayment Reduction under health insurance. There are no accurate statistics on the number of cases in Korea, but it is very rare, at the level of a few cases per year. Diagnosis including genetic testing and treatment are available at major pediatric hematology-immunology centers.
Almost all patients are male. Female patients are extremely rare and are exceptional cases due to X-chromosome monosomy (45,X), severe X inactivation or autosomal-like mutations.
WASP is expressed throughout hematopoietic cells and, after being activated via CDC42/GTPase, binds the Arp2/3 complex to induce F-actin (filamentous actin) polymerization. This cytoskeletal rearrangement is essential for immune synapse formation, T-cell activation, cell migration, phagocytosis and platelet function.
In WASP deficiency, immune synapse formation in T cells is incomplete, impairing T-cell activation and proliferation. Regulatory T-cell (Treg) function is also reduced, increasing the tendency toward autoimmunity.
In platelets, WASP deficiency impairs platelet production (thrombopoiesis), platelet activation and cytoskeletal rearrangement. Reduced platelet size (microthrombocytopenia) and functional abnormalities are characteristic. Platelet destruction by autoantibodies also contributes to thrombocytopenia.
In B cells, WASP deficiency impairs B-cell receptor (BCR) signaling and antibody responses. In NK cells, cytotoxic function is reduced.
The classic triad of WAS is ①bleeding tendency due to microthrombocytopenia, ②eczema and ③recurrent infections. Unlike classic WAS, in which all three appear, there is also the XLT (X-linked thrombocytopenia) form, in which thrombocytopenia is the only main symptom.
Thrombocytopenia (platelet count usually 20,000–80,000/μL) causes petechiae, ecchymoses, bloody stools and intracranial hemorrhage. Intracranial hemorrhage can be a fatal complication in infancy.
Bacterial (pneumococcus, Haemophilus), viral (EBV, CMV, herpes simplex), opportunistic (PCP, Candida) and protozoal infections recur. With age, the immunodeficiency deepens and the frequency and severity of infections increase.
In about 20–40%, autoimmune cytopenias (hemolytic anemia, thrombocytopenia), vasculitis, nephritis and inflammatory bowel disease occur and worsen prognosis. The risk of malignancies such as EBV-related B-cell lymphoma is markedly high.
Generalized eczematous skin rash, petechiae and ecchymoses are characteristic. Findings of infection-related otorrhea, oral thrush and pneumonia appear. Splenomegaly and lymphadenopathy may be observed.
Reduced platelet count and small platelets (reduced MPV) are central to the diagnosis. On immunoglobulin testing, a characteristic abnormal pattern of low IgM, increased IgA and IgE and normal IgG is typical. Reduced antibody responses to polysaccharide antigens are characteristic. WASP protein expression testing (flow cytometry) confirms loss or reduction of the protein.
Bone marrow biopsy may show normal megakaryocytes but reduced platelet production. Lymph node biopsy shows abnormal lymphocyte architecture.
When thrombocytopenia is found in a newborn, differential diagnosis of X-linked thrombocytopenias including WAS is required. Small platelets (reduced MPV) are an important finding particularly suggestive of WAS.
WAS is actively suspected in boys with microthrombocytopenia, eczema and recurrent infections. If there are male maternal relatives who died early with similar symptoms (X-linked family history), genetic testing is performed immediately.
Mothers of patients with WAS should have genetic testing to determine whether they carry a WAS gene mutation. Because WAS occurs with a 50% probability in every male child of a carrier woman, prenatal diagnosis is needed in pregnancy.
Clinical diagnosis is made in boys by the combination of microthrombocytopenia (including reduced MPV) + eczema + recurrent immunodeficiency-related infections. The WAS scoring system (Zhu et al., 1997) is used to classify severity on a scale of 0–5.
WASP protein expression in peripheral blood mononuclear cells is confirmed by flow cytometry or Western blot. Loss of protein expression strongly suggests a WAS gene mutation, which is confirmed by molecular testing.
Sequencing of the WAS gene (Xp11.22-23) and MLPA are the standard confirmatory methods. Diagnosis is also possible with a primary immunodeficiency NGS panel. When a novel mutation is identified, pathogenicity is confirmed by functional testing (WASP protein expression and actin polymerization function).
Immunoglobulin quantification, lymphocyte subset analysis, testing of antibody responses to polysaccharide antigens and T-cell function testing (proliferative response) are performed to assess the degree of immunodeficiency.
The curative treatment for classic WAS is hematopoietic stem cell transplantation (HSCT). Early transplantation, before age 5 if possible and ideally before age 2, is recommended. Transplantation from an HLA-matched sibling donor gives the best results, and good outcomes are also reported for matched unrelated donor transplantation. When transplantation succeeds, the immunodeficiency, thrombocytopenia and eczema are all corrected.
Regular IVIG administration compensates for antibody deficiency. PCP prophylaxis (TMP-SMX) and prophylactic antifungals and antivirals are needed. Topical steroids and moisturizers are applied for skin eczema. Live vaccines are absolutely contraindicated.
Platelet transfusion is given for acute bleeding or before invasive procedures. Splenectomy temporarily raises the platelet count, but performing it before transplantation is not recommended.
WAS gene therapy using lentiviral vectors is demonstrating safety and efficacy in clinical trials, and good results have been reported from European clinical trials since 2019.
The median survival of untreated patients with classic WAS is about 15 years. The main causes of death are intracranial hemorrhage, severe infection and EBV-related malignant lymphoma. The risk of malignancy in patients with WAS is more than 100 times higher than in healthy individuals.
With identical sibling donor transplantation before age 5, 5-year survival is 80–90% or higher. Outcomes of matched unrelated donor transplantation have also improved, to the 70–80% level. When transplantation succeeds, the immunodeficiency and thrombocytopenia are corrected and the risk of malignancy is also greatly reduced.
X-linked thrombocytopenia (XLT) is milder than classic WAS, and some patients can survive into adulthood without transplantation, but continuous monitoring for intracranial hemorrhage, autoimmune complications and malignancy risk is needed.
Carrier genetic testing and genetic counseling for mothers of patients with WAS are essential. Carrier women should be counseled that WAS occurs in 50% of their male children. Because about 1/3 are de novo mutations, WAS should be suspected in boys with thrombocytopenia even without a family history.
In pregnancies of confirmed carrier women, fetal WAS gene analysis is performed by CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation). It is also possible to prevent implantation of affected male embryos with PGT-M in in vitro fertilization cycles.
Prevention of head trauma (consider wearing a protective helmet), contraindication of live vaccines, regular IVIG administration, prompt aggressive antibiotic treatment of infections, skin care to prevent worsening of eczema and regular monitoring for malignancy are the core of preventive management.